Subclinical infections with Crimean-Congo hemorrhagic fever virus, Turkey.
Hemorrhagic fever (Health aspects)
Infection (Health aspects)
Medical research (Health aspects)
Medicine, Experimental (Health aspects)
|Publication:||Name: Emerging Infectious Diseases Publisher: U.S. National Center for Infectious Diseases Audience: Academic; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2012 U.S. National Center for Infectious Diseases ISSN: 1080-6040|
|Issue:||Date: April, 2012 Source Volume: 18 Source Issue: 4|
|Product:||Product Code: 8000200 Medical Research; 9105220 Health Research Programs; 8000240 Epilepsy & Muscle Disease R&D NAICS Code: 54171 Research and Development in the Physical, Engineering, and Life Sciences; 92312 Administration of Public Health Programs|
Crimean-Congo hemorrhagic fever virus (CCHFV) infection was first
recognized in Turkey in 2002. Since that time, the number of diagnosed
cases has increased to the magnitude of an outbreak with major public
health consequences (1,2). Although the clinical spectrum may change
from asymptomatic infection to severe hemorrhagic disease, most studies
to date have included only symptomatic cases (1-6). Therefore, the true
incidence of infection with the virus, the full spectrum of severity of
disease, and its epidemiologic features are unknown. The purpose of our
study was to investigate the seroprevalence of CCHFV infection in a
sufficiently large sample representative of the region affected during
this outbreak in Turkey and to describe the main epidemiologic features,
including the proportion of subclinical cases.
During January-April 2009, we conducted a survey that included obtaining venous blood samples from participants. The study sample was selected by using a random geographic cluster sampling stratified by age and sex from rural residential areas of Turkey where 99.5% of CCHF cases were reported (Figure 1). Only adults >18 years of age who were living in the study area for [greater than or equal to] 1 year were eligible for the study. The study was approved by the Central Ethics Committee, and informed consent was obtained from all participants. A study questionnaire included questions on demographics, socioeconomic status, behavior characteristics, medical history, known risk factors for CCHFV infection, and participants' awareness of the outbreak and infection prevention methods.
Serum samples were tested for IgG against CCHFV at the Virology Reference Laboratory of the Refik Saydam National Public Health Agency, (Ankara, Turkey) by using a commercial ELISA kit (Vector-Best, Novosibrisk, Russia). Although the sensitivity and specificity of the kit were not specified by the manufacturer, studies that used this method have reported a sensitivity of 87%-98.3% and a specificity of 99%-100% (7,8). We defined subclincial cases as those in persons who were seropositive although they were not given a diagnosis or had not had severe symptoms compatible with CCHF at any time.
In addition, we compared information in our database with that in the database of reported cases at the Ministry of Health, Turkey. We used the [chi square] test, t test, and Mann-Whitney U test for univariate statistical comparisons, as appropriate. Multivariable logistic regression was used to assess independent risk factors for seropositivity. We used the direct standardization method to adjust age-specific seropositivity rates for our study population with the age composition of the entire outbreak region. This adjustment enabled us to calculate expected numbers of infected (seropositive) persons in the outbreak region (online Technical Appendix, wwwnc.cdc.gov/EID/pdfs/11-1374-Techapp.pdf). Clinically diagnosed cases were compared with expected numbers of infections, and an observed:expected ratio was calculated.
The survey included 3,671 adults of whom 3,557 (97%) provided blood samples for serologic analysis. The mean [+ or -] SD age of the study population was 44.3 [+ or -] 16.2 years, the female:male ratio was 1.04 (51%:49%), and the most common occupation was farming (52.4%). Only 18.2% had a history of tick bite.
Of 3,557 serum samples tested, 356 (10%) were positive for IgG against CCHFV. Mean [+ or -] SD age was 43.4 [+ or -] 16.2 years for seronegative persons and 52 [+ or -] 17.1 years for seropositive persons (p<0.001). Categorizing persons by age in 10-year intervals showed that seropositivity increased with age (p<0.001) (Figure 2). Univariate analysis showed that seropositive persons had less education (p<0.001), were more likely to be involved in farming, (p<0.001), and had a higher frequency of tick bites (p<0.001) than seronegative persons (Table 1). Animal husbandry as an occupation and a history of hunting were not more frequent among seropositive persons than among seronegative persons. A high proportion of seropositive persons (73.8%) and seronegative persons (71.3%), claimed that they had sufficient information about the infection and how to protect themselves (p = 0.329). Multivariable analysis results showed that an age >60 years, less schooling, farming as an occupation, and a history of tick bites were independent risk factors for seropositivity (Table 2).
[FIGURE 1 OMITTED]
None of the study population had been given a diagnosis of CCHF or had been hospitalized for an acute febrile illness or severe bleeding compatible with CCHF. During 2002-2009, a total of 1,806 adults were given a diagnosis of CCHF in the outbreak region where we conducted our study (Ministry of Health, Turkey). Direct standardization of age-specific seroprevalence rates for the study population with ages of persons in the entire region showed that 15,156 infections would be expected during 2002-2008 (observed:expected ratio 0.12; 95% CI 0.114-0.125). This finding shows that only 12% of the infections were diagnosed and 88% were subclinical.
We found that the seroprevalence of CCHF in the study region was 10%. Hoogstraal et al. reported that the expected seroprevalence of CCHF was [approximately equal to] 10% during epidemics (9). In a small survey in Turkey, IgG against CCHFV was detected in 12.8% of the population in high-risk areas (10). Our study showed that the distribution of seropositivity increased with age (Figure 2). This finding was unexpected and showed that CCHF was present in the region long before it was recognized. However, we could not assess whether incidence or severity were amplified in recent years, which led to its detection in 2002. Seroprevalence surveys with representative samples at regular intervals may be the only way for determining if incidence of infection has increased.
Another useful result from this study was the ability to predict that [approximately equal to] 90% of CCHFV infections were subclinical (online Technical Appendix). This finding has clinical and epidemiologic implications. First, it shows that the spectrum of severity is highly skewed toward milder disease, although CCHF is believed to be a severe infection similar to other hemorrhagic fevers such as those caused by Ebola or Marburg viruses. Epidemiologically, information about subclinical cases is necessary for estimating the level of herd immunity in the population and predicting the characteristics of the outbreak. Finally, we do not know precisely why CCHF develops into a serious or fatal disease in some patients but is only a mild or asymptomatic in others (11). Some studies have shown that factors such as immune response of the host, viral load, or lack of some receptors may affect the clinical form of infection (12,13). Some authors have suggested that geographic variation in pathogenicity of the virus (14) may also be a factor in severity, although the supporting data are lacking (15). Therefore, timely detection and comparison of different clinical groups will be helpful in understanding the pathogenicity of the virus or host responses and developing effective treatments for infection.
This study was supported by the Scientific and Technological Research Council of Turkey.
Dr Bodur is chief of the Infectious Diseases and Clinical Microbiology Department at Ankara Numune Education and Research Hospital. His primary research interests are CrimeanCongo hemorrhagic fever, brucellosis, chronic hepatitis, and nosocomial infections.
(1.) Bakir M, Ugurlu M, Dokuzoguz B, Bodur H, Tasyaran MA, Vahaboglu H, et al. Crimean-Congo haemorrhagic fever outbreak in middle Anatolia: a multicenter study of clinical features and outcome measures. J Med Microbiol. 2005;54:385-9. http://dx.doi.org/10.1099/jmm.0.45865-0
(2.) Yilmaz GR, Buzgan T, Irmak H, Safran A, Uzun R, Cevik MA, et al. The epidemiology of Crimean-Congo hemorrhagic fever in Turkey, 2002-2007. Int J Infect Dis. 2009;13:380-6. http://dx.doi. org/10.1016/j.ijid.2008.07.021
(3.) Elaldi N, Bodur H, Ascioglu S, Celikbas A, Ozkurt Z, Vahaboglu H, et al. Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. J Infect. 2009;58:238-44. http://dx.doi.org/10.1016/jjinf.2009.01.014
(4.) Ozkurt Z, Kiki I, Erol S, Erdem F, Yilmaz N, Parlak M, et al. Crimean-Congo hemorrhagic fever in eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect. 2006;52:20715. http://dx.doi.org/10.1016/jjinf.2005.05.003
(5.) Jabbari A, Besharat S, Abbasi A, Moradi A, Kalavi K. Crimean-Congo hemorrhagic fever: case series from a medical center in Golestan Province, northeast of Iran (2004). Indian J Med Sci. 2006;60:3279. http://dx.doi.org/10.4103/0019-5359.26609
(6.) Alavi-Naini R, Moghtaderi A, Koohpayeh HR, Sharifi-Mood B, Naderi M, Metanat M, et al. Crimean-Congo hemorrhagic fever in southeast of Iran. M. J Infect. 2006;52:378-82. http://dx.doi. org/10.1016/j.jinf.2005.07.015
(7.) Saijo M, Qing T, Niikura M, Maeda A, Ikegami T, Prehaud C, et al. Recombinant nucleoprotein-based enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to CrimeanCongo hemorrhagic fever virus. J Clin Microbiol. 2002;40:1587-91. http://dx.doi.org/10.1128/JCM.40.5.1587-1591.2002
(8.) Emmerich P, Avsic-Zupanc T, Chinikar S, Saksida A, Thome-Bolduan C, Langroudi AG, et al. Early serodiagnosis of acute human Crimean-Congo hemorrhagic fever virus infections by novel capture assays. J Clin Virol. 2010;48:294-5. http://dx.doi.org/10.1016/j. jcv.2010.05.002
(9.) Hoogstraal H. The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa. J Med Entomol. 1979;15:307-417.
(10.) Gunes T, Engin A, Poyraz O, Elaldi N, Kaya S, Dokmetas I, et al. Crimean-Congo hemorrhagic fever virus in high-risk population, Turkey. Emerg Infect Dis. 2009;15:461-4. http://dx.doi.org/10.3201/eid1503.080687
(11.) Cevik MA, Erbay A, Bodur H, Gulderen E, Bastug" A, Kubar A, et al. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int J Infect Dis. 2008;12:374-9. http:// dx.doi.org/10.1016/j.ijid.2007.09.010
(12.) Cevik MA, Erbay A, Bodur H, Eren SS, Akinci E, Sener K, et al. Viral load as a predictor of outcome in Crimean-Congo hemorrhagic fever. Clin Infect Dis. 2007;45:e96-100. http://dx.doi. org/10.1086/521244
(13.) Saksida A, Duh D, Wraber B, Dedushaj I, Ahmeti S, Avsic-Zupanc T. Interacting roles of immune mechanisms and viral load in the pathogenesis of Crimean-Congo hemorrhagic fever. Clin Vaccine Immunol. 2010;17:1086-93. http://dx.doi.org/10.1128/CVI.00530-09
(14.) Vorou R, Pierroutsakos IN, Maltezou HC. Crimean-Congo haemorrhagic fever. Curr Opin Infect Dis. 2007;20:495-500. http://dx.doi. org/10.1097/QCO.0b013e3282a56a0a
(15.) Burt FJ, Swanepoel R. Molecular epidemiology of African and Asian Crimean-Congo haemorrhagic fever isolates. Epidemiol Infect. 2005;133:659-66. http://dx.doi.org/10.1017/S0950268805003730
Author affiliations: Ankara Numune Education and Research Hospital, Ankara, Turkey (H. Bodur, E. Akinci, P. Onguru); Hacettepe University Medical School, Ankara (S. Ascioglu); and Refik Saydam National Public Health Agency, Ankara (Y. Uyar)
DOI: http://dx.doi.org/ 10.3201/eid1804.111374
Address for correspondence: Hiirrem Bodur, Infectious Diseases and Clinical Microbiology Department, Ankara Numune Education and Research Hospital, 06100 Ankara, Turkey; email: hurrembodur@gmail. com
Table 1. Characteristics of study population tested for CCHFV, Turkey, January-April 2009 * Seronegative, Characteristic n = 3,201 Sex F 1,634 (51.0) M 1,567 (49.0) Age, y, mean [+ or -] SD 43.38 [+ or -] 15.81 18-29 765 (23.9) 30-39 721 (22.5) 40-49 616 (19.2) 50-59 511 (16.0) 60-69 352 (11.0) [greater than or equal to] 70 236 (7.4) Education None 607 (19.0) Elementary school 1,873 (58.8) High school or university 707 (22.2) Occupation Unemployed 618 (19.5) Farming 1,186 (37.5) Animal husbandry 553 (17.5) Other ([dagger]) 809 (25.5) Persons living in same residence, mean [+ or -] SD 5.01 [+ or -] 2.54 History of hunting 548 (17.6) History of tick bite 540 (17.0) Sufficiently informed about CCHFV 2,269 (71.3) Seropositive, Characteristic n = 356 p value Sex F 168 (47.2) 0.167 M 188 (52.8) Age, y, mean [+ or -] SD 51.97 [+ or -] 17.14 <0.001 18-29 46 (12.9) <0.001 30-39 55 (15.4) 40-49 55 (15.4) 50-59 57 (16.0) 60-69 72 (20.2) [greater than or equal to] 70 71 (19.9) Education None 105 (29.7) <0.001 Elementary school 214 (60.6) High school or university 34 (9.6) Occupation Unemployed 66 (18.9) <0.001 Farming 174 (49.9) Animal husbandry 58 (16.6) Other ([dagger]) 51 (14.6) Persons living in same residence, mean [+ or -] SD 5.28 [+ or -] 2.97 0.177 History of hunting 54 (15.5) 0.325 History of tick bite 105 (29.7) <0.001 Sufficiently informed about CCHFV 261 (73.7) 0.329 * Values are no. (%) unless otherwise indicated. CCHFV, Crimean- Congo hemorrhagic fever virus. ([dagger]) Retired, civil servant, factory, worker, or housewife. Table 2. Multivariable logistic regression of risk factors for infection with CCHFV, Turkey, January-April 2009 * Characteristic Odds ratio (95% CI) Age, y 18-29 1 30-39 0.965 (0.630-1.480) 40-49 1.034 (0.669-1.599) 50-59 1.297 (0.832-2.023) 60-69 2.687 (1.723-4.191) [greater than or equal to] 70 4.176 (2.638-6.611) Education None 1 Elementary school 0.977 (0.736-1.297) High school or university 0.580 (0.357-0.942) Occupation Unemployed and other ([dagger]) 1 Farming 1.688 (1.301-2.190) Animal husbandry 1.299 (0.922-1.832) History of tick bite 2.292 (1.768-2.971) * CCHFV, Crimean-Congo hemorrhagic fever virus. ([dagger]) Retired, civil servant, factory worker, or housewife. Figure 2. Distribution of Crimean-Congo hemorrhagic fever virus (CCHFV)-positive persons, by age group, Turkey, January-April 2009. p<0.001, by trend test. % Positive for CCHFV lgG Age, y 18-29 12.9% 30-39 15.4% 40-9 15.4% 50-59 16.0% 60-69 20.2% [greater than or equal to] 70 19.9% Note: Table made from bar graph.
|Gale Copyright:||Copyright 2012 Gale, Cengage Learning. All rights reserved.|